GENE MUTATIONS AND MICRORNA SIGNATURE IN MYELODYSPLASTIC SYNDROMES DURING AZACITIDINE AND LENALIDOMIDE THERAPY

被引：0
|
作者：
Follo, M. Y. [1 ]
Pellagatti, A. [2 ]
Armstrong, R. N. [2 ]
Ratti, S. [1 ]
Mongiorgi, S. [1 ]
Astolfi, A. [3 ,4 ]
Indio, V. [3 ]
De Fanti, S. [5 ]
Russo, D. [6 ]
Gobbi, M. [7 ]
Miglino, M. [7 ]
Bochicchio, M. T. [8 ]
Martinelli, G. [9 ]
Parisi, S. [8 ]
Pession, A. [4 ]
Cavo, M. [8 ]
Cocco, L. [1 ]
Manzoli, L. [1 ]
Boultwood, J. [2 ]
Finelli, C. [8 ]
机构：
[1] Univ Bologna, Dept Biomed & Neuromotor Sci, Cellular Signalling Lab, Bologna, Italy
[2] Univ Oxford, John Radcliffe Hosp, Nuffield Div Clin Lab Sci, Bloodwise Mol Haematol Unit,Dept Med, Oxford, England
[3] Univ Bologna, Interdept Ctr Canc Res G Prodi, Bologna, Italy
[4] Univ Bologna, S Orsola Malpighi Hosp, Pediat Hematol & Oncol Unit, Bologna, Italy
[5] Univ Bologna, Dept Biol Geol & Environm Sci, Bologna, Italy
[6] Univ Brescia, Chair Hematol, Unit Blood Dis & Stem Cell Transplantat, Dept Clin & Expt Sci, Brescia, Italy
[7] Univ Genoa, Dept Hematol & Oncol, Genoa, Italy
[8] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy
[9] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, FC, Italy
来源：
HAEMATOLOGICA | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO050
引用
收藏
页码：S43 / S44
页数：2
相关论文
共 50 条
  • [41] Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes
    Follo, Matilde Y.
    De Stefano, Alessia
    Mongiorgi, Sara
    Casalin, Irene
    Cappellini, Alessandra
    Ratti, Stefano
    Pellagatti, Andrea
    Fogli, Miriam
    Cavo, Michele
    Manzoli, Lucia
    Cocco, Lucio
    Boultwood, Jacqueline
    Parisi, Sarah
    Paolini, Stefania
    Curti, Antonio
    Finelli, Carlo
    BLOOD, 2022, 140 : 6905 - 6906
  • [42] Azacitidine and Lenalidomide Combination In Higher-Risk Myelodysplastic Syndromes-Preliminary Results Of The Vilen-01 Protocol
    Mittelman, Moshe
    Filanovsky, Kalman
    Rosenbaum, Hanna
    Raanani, Pia
    Braester, Andrei
    Goldschmidt, Neta
    Hellman, Ilana
    Kirgner, Ilya
    Perrii, Chava
    Oster, Howard S.
    BLOOD, 2013, 122 (21)
  • [43] Circulating Exosomal MicroRNA-21 As a Potential Biomarker That May Predict Response to Azacitidine Treatment in Myelodysplastic Syndromes
    Min, Yoo-Hong
    Yoon, Sulhee
    Hwang, Doh Yu
    Kim, Yundeok
    Kim, Yeo-Kyeoung
    Kim, Yuri
    Cho, Jae Yong
    Kim, Jin Seok
    Kim, Soo Jeong
    Cheong, June-Won
    Kim, Hyeoung Joon
    BLOOD, 2011, 118 (21) : 1625 - 1625
  • [44] Preliminary results from a phase I study of Revlimid® (Lenalidomide) in combination with Vidaza® (Azacitidine) in patients with advanced myelodysplastic syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan
    Cuthbertson, David
    Paquette, Ronald
    Loughran, Thomas
    Maciejewski, Jaroslaw P.
    BLOOD, 2007, 110 (11) : 437A - 437A
  • [45] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    BLOOD, 2008, 112 (11) : 88 - 89
  • [46] CLINICAL RESPONSE TO THE ASSOCIATION OF AZACITIDINE AND LENALIDOMIDE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES. A RANDOMIZED PHASE II MULTICENTER STUDY
    Finelli, C.
    Clissa, C.
    Follo, M. Y.
    Stanzani, M.
    Parisi, S.
    Avanzini, P.
    Bosi, C.
    Castagnari, B.
    Candoni, A.
    Crugnola, M.
    Giannini, M. B.
    Gobbi, M.
    Leonardi, G.
    Rigolin, G. M.
    Russo, D.
    Tosi, P.
    Visani, G.
    Cocco, L.
    Cavo, M.
    LEUKEMIA RESEARCH, 2015, 39 : S50 - S50
  • [47] Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
    Zeidan, Amer M.
    Gore, Steven D.
    Komrokji, Rami S.
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (03) : 251 - 254
  • [48] SAFETY PROFILE OF AZACITIDINE IN THE TREATMENT OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKAEMIA
    Minoia, C.
    Sgherza, N.
    Greco, G.
    Buquicchio, C.
    Loseto, G.
    de Fazio, V.
    Iacobazzi, A.
    Rana, A.
    Merchionne, F.
    Tarantini, G.
    Pavone, V.
    Guarini, A.
    HAEMATOLOGICA, 2014, 99 : 619 - 619
  • [49] The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).
    Kenealy, Melita K.
    Seymour, John F.
    Linda, Cowan
    Milner, Alvin
    Giri, Pratyush
    Ho, Shir-Jing
    Benson, Warwick
    Nicol, Andrew
    Campbell, Philip
    Prosser, Ian
    Underhill, Craig
    Cunningham, Ilona
    Mills, Anthony K.
    Szer, Jeffrey
    Presgrave, Peter
    Filshie, Robin
    BLOOD, 2009, 114 (22) : 695 - 695
  • [50] The clinical characteristics, gene mutations and outcomes of myelodysplastic syndromes with diabetes mellitus
    Xu, Fanhuan
    Jin, Jiacheng
    Guo, Juan
    Xu, Feng
    Chen, Jianan
    Liu, Qi
    Song, Luxi
    Zhang, Zheng
    Zhou, Liyu
    Su, Jiying
    Xiao, Chao
    Zhang, Yumei
    Yan, Meng
    He, Qi
    Wu, Dong
    Chang, Chunkang
    Li, Xiao
    Wu, Lingyun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (02)
12345